Between 4th and 6th June, TVT (Transcatheter Valve Therapies) presented by CRF (Cardiovascular Research Foundation) took place in Chicago, US. The new and novel TMVR developed by SINOMED called ‘Accufit™’ was introduced for the first time outside of Asia and Europe.
On 4th June, SINOMED’s TMVR was introduced by Patrick W. Serruys among other TMVR devices such as Tiara, Fortis, Tendyne and CardiaQ during the session ‘New mitral technology II: transcatheter mitral valve replacement’. Moderators of this session were Nicolo Piazza (McGill University Health Center, Montreal Canada) and Gregg Stone (Columbia University Medical Center, New York, US). Furthermore, several experts in this field including Michael Argenziano, Vinayak Bapat, Philipp Blanke, Ted E. Feldman, Mayra Guerrero and Lars Sondergaard were participated as discussants. The presentation was received positively by the large audience in attendance.
At the moment, SINOMED is finalizing its acute animal studies. The EU First-In-Man trial will be initiated in begin 2016.
SINOMED’s TMVR: AccuFit™
AccuFit™ Transcatheter Mitral Valve Replacement (TMVR) device developed by SINOMED features a pericardial valve mounted on a super elastic nitinol frame. It is designed specifically to address the challenges confronting minimally-invasive mitral valve replacement. It has a patented circumferential-coapt leaflet design to eliminate both central leakage and paravalvular leakage (PVL) in case valve frame is deformed post valve implantation. The “leveled” anchoring feature design minimizes PVL, SAM, and provides improved valve stability.
The Cardiovascular Research Foundation’s (CRF’s) evidence-based research, innovative technologies, and committed clinicians have united to advance a subspecialty that has had a vast impact on public health—saving lives and allowing countless numbers of patients to avoid surgery.CRF is a global leader at the forefront of today’s treatments and technologies in the fight against heart disease. Since its inception in 1991, CRF has played a pivotal role in advancing the understanding and treatment of cardiovascular disease, realizing dramatic improvements by establishing the safe use of new technologies, drugs, and therapies. Guided by visionary physicians who are passionate about advancing the field, our mission is to improve the survival and quality of life for those suffering from heart disease.
For more information, please visit: http://www.crf.org/tvt/